South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

astellas pharma (pty) ltd - capsules - see ingredients - each capsule contains enzalutamide 40,0 mg

Singapore - English - HSA (Health Sciences Authority)

astellas pharma singapore pte. ltd. - solifenacin succinate - tablet, film coated - 10mg/tablet - solifenacin succinate 10 mg

Singapore - English - HSA (Health Sciences Authority)

astellas pharma singapore pte. ltd. - solifenacin succinate - tablet, film coated - 5mg/tablet - solifenacin succinate 5 mg

Israel - English - Ministry of Health

astellas pharma international b.v., israel - enzalutamide - capsules soft - enzalutamide 40 mg - enzalutamide - xtandi is indicated for:• the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc).• the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.• the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Israel - English - Ministry of Health

astellas pharma international b.v., israel - mirabegron - tablets prolonged release - mirabegron 25 mg - mirabegron - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (oab) syndrome

Israel - English - Ministry of Health

astellas pharma international b.v., israel - mirabegron - tablets prolonged release - mirabegron 25 mg - mirabegron - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (oab) syndrome

Israel - English - Ministry of Health

astellas pharma international b.v., israel - mirabegron - tablets prolonged release - mirabegron 50 mg - mirabegron - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (oab) syndrome

Israel - English - Ministry of Health

astellas pharma international b.v., israel - mirabegron - tablets prolonged release - mirabegron 50 mg - mirabegron - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (oab) syndrome

Israel - English - Ministry of Health

astellas pharma international b.v., israel - micafungin as sodium - powder for concentrate for solution for infusion - micafungin as sodium 50 mg - micafungin - adults, adolescents ≥ 16 years of age and elderly:- treatment of invasive candidiasis.- treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate.- prophylaxis of candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation.children (including neonates) and adolescents < 16 years of age:- treatment of invasive candidiasis.- prophylaxis of candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation.the decision to use mycamine should take into account a potential risk for the development of liver tumours. mycamine should therefore only be used if other antifungals are not appropriate.

Israel - English - Ministry of Health

astellas pharma international b.v., israel - enzalutamide - film coated tablets - enzalutamide 40 mg - enzalutamide - xtandi is indicated for:• the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc).• the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.• the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.•the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy